Company
Prescient Therapeutics Ltd
ASX:PTX
Prescient Therapeutics Ltd is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies. The company’s technologies emanate from prestigious world class centres including Yale, Penn, Oxford and Moffitt.
88 stories
Prescient Therapeutics provides PTX-100 trial update, readies for investor briefing
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a partial response, meaning the size of the cancer tumour has decreased.
Prescient Therapeutics' PTX-100 expansion cohort continues to deliver on safety and clinical movement
“It is very exciting to see PTX-100 show clinical activity in a patient population that is notoriously difficult to treat, and where these patients have failed several lines of prior therapies," said CEO and MD Steven Yatomi-Clarke.
Prescient Therapeutics A$2.5 million top-up placement brings raise total to A$11.3 million
Together with the A$8.76 million from the share purchase plan, Prescient has raised roughly A$11.3 million to develop its deep pipeline of cancer therapies.
Prescient Therapeutics exceeds SPP target, delivers top-up placement to accommodate demand
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing director and CEO Steven Yatomi-Clarke.
Prescient Therapeutics unveils novel adjuvant for enhancing cellular immunotherapy: CellPryme-A
"CellPryme-A is the latest in a portfolio of platform cell technologies that can not only create innovative programs for Prescient, but are also enabling technologies that open up third party commercialisation opportunities," said MD and CE
Prescient Therapeutics to unveil CellPryme-A platform at CAR-TCR summit in Boston
The company’s novel, ready-for-the-clinic CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing.
Prescient Therapeutics to collaborate with largest cancer centre in the US to develop blood cancer treatment
"We believe that OmniCAR is a transformational platform for cellular immunotherapy, and we look forward to testing the potential of this promising TCR-like binder for blood cancers," MD and CEO Steven Yatomi-Clarke said.
Prescient Therapeutics enters into OmniCAR cell production agreement with Q-Gen Cell
Q-Gen Cell will produce and deliver the OmniCAR cell lines from its Brisbane facility to be used for Prescient's upcoming clinical trials.
Challenging the pace of change in healthcare: Prescient Therapeutics
“The fact of the matter is there are people walking around now who shouldn’t be alive, but they are because of our trials, which is really rewarding. You don’t get that in investment banking."
Prescient Therapeutics’ PTX-100 for peripheral T-cell lymphoma treatment granted US orphan drug status
The designation brings considerable benefits including guaranteed market exclusivity for seven years and a waiver of Prescription Drug User Fee Act fees for orphan drugs, valued at over US$3.1 million in 2022.
Prescient Therapeutics granted key US patent for OmniCAR portfolio of therapies
"This patent is a key plank in the protection of the OmniCAR platform, especially in the US, which is the world’s largest healthcare market,” MD and CEO Steven Yatomi-Clarke said.
Prescient Therapeutics signs CAR-T agreement with Peter Mac Cancer Centre
The new CAR-T agreement for the OmniCAR platform adds to Prescient’s existing and related research program with Peter Mac into Cell Therapy Enhancements.
Prescient Therapeutics licenses Pennsylvania and Oxford university technologies to create universal cell therapy platform
The company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell therapy products for new indications, and improve the cost, time and of effectiveness of delivering cell therapy products.
Prescient Therapeutics wins US patent for its novel cancer-blocking compound
The company's lead clinical compound blocks an important tumour survival pathway known as Akt.
Prescient Therapeutics granted European patent for its cancer therapy
PTX-200 is well advanced in the clinic with trials moving to phase 2.
Prescient Therapeutics to reveal results from cancer trial
The halt will remain in place until Thursday 6th April 2017.
Prescient Therapeutics gets positive signals from anti-cancer trial
Treated 3 patients with acute myeloid leukaemia using PTX-200.
Prescient Therapeutics begins dose escalation for ovarian cancer
Prescient Therapeutics (ASX:PTX) has dosed its first patient at the next dose level of PTX-200 in the dose escalation stage of its Phase 1b/2 trial for the treatment of metastatic ovarian cancer.